Some previous studies reported that EPO treatment improved glucose tolerance in high-fat diet-induced obesity and insulin-resistant model animals, suggesting the possibility that EPO is a novel therapeutic agent for insulin resistance [20,21,22]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.